Coagulopathy and DIC in burn patients

For venous thromboembolism prophylaxis, see [[venous-thromboembolism-prophylaxis-in-burns]].

Overview

Burn-induced coagulopathy encompasses a spectrum of hemostatic derangements ranging from subclinical platelet consumption and factor depletion to fulminant disseminated intravascular coagulation (DIC). The coagulation system in burn patients is stressed by tissue factor release from damaged tissue, systemic inflammation driving thrombin generation, consumptive depletion of coagulation factors and platelets, dilutional effects from massive fluid resuscitation, and hypothermia. The onset of coagulopathy in severely burned patients is an early indicator of mortality risk that persists throughout clinical recovery ^[1].

Pathophysiology

The tissue factor pathway is the primary initiator of burn-related coagulation activation. Extensive thermal tissue destruction exposes subendothelial tissue factor, triggering the extrinsic coagulation cascade. The resultant thrombin generation drives simultaneous clotting and fibrinolysis, producing the consumptive coagulopathy characteristic of DIC ^[8]. In DIC, uncontrolled thrombin generation overwhelms natural anticoagulant mechanisms (antithrombin, protein C), leading to widespread microvascular thrombosis and secondary fibrinolysis. The result is paradoxical: simultaneous organ-threatening microthrombosis and life-threatening hemorrhage from factor and platelet consumption ^[8]. The immune system and coagulation system share common regulatory pathways, and the massive inflammatory response to burns amplifies coagulation dysregulation through cytokine-mediated activation of endothelial cells and monocytes ^[5].

Diagnosis

ISTH DIC Scoring

The International Society on Thrombosis and Haemostasis overt DIC scoring system remains the standard diagnostic framework ^[7]. The score incorporates platelet count, D-dimer or fibrin degradation products, prolonged prothrombin time, and fibrinogen level. A score of 5 or greater is consistent with overt DIC. The ISTH system was developed across mixed critically ill populations; no DIC scoring system has been validated specifically for burns. The Japanese Association for Acute Medicine DIC criteria offer an alternative scoring approach that may capture DIC earlier in the disease course ^[3].

Viscoelastic Testing

Rotational thromboelastometry (ROTEM) provides rapid, point-of-care assessment of coagulation function in burn patients. A study analyzing the correlation between burn severity and ROTEM parameters demonstrated strong negative correlations between the burn index and clot firmness in both EXTEM (extrinsic cascade) and FIBTEM (fibrinogen-specific) assays (rho = -0.946 to -0.721) ^[2]. Severe burns (burn index greater than 15) were associated with significantly decreased clot firmness across all ROTEM variables, suggesting that viscoelastic testing may provide real-time coagulation assessment beyond conventional laboratory panels ^[2].

In practice, decreased EXTEM and FIBTEM clot firmness on admission ROTEM signals the need for fibrinogen replacement (cryoprecipitate or fibrinogen concentrate) and platelet transfusion before operative intervention. A FIBTEM A10 below 10 mm suggests critical hypofibrinogenemia requiring immediate correction. This threshold allows goal-directed correction before the patient reaches the operating room, rather than waiting for conventional lab results that may take 45-60 minutes to return.

Clinical Prediction Models

A clinical prediction model for DIC in electrical burn patients identified four independent risk factors: injury voltage, shock upon admission, osteofascial compartment syndrome within 1 day of injury, and D-dimer level within 24 hours (AUC 0.88) ^[6]. A separate prediction model for DIC after severe thermal burns identified total burn area, full-thickness burn area, and early shock as key predictors ^[1].

Management

Treat the Underlying Cause

Treatment of burn-associated DIC is primarily directed at the underlying cause: wound excision, infection control, and hemodynamic stabilization. Removing the tissue factor source through early excision reduces the ongoing stimulus for thrombin generation. Infection is a major secondary driver of DIC in burns; source control and appropriate antimicrobials are essential.

Component Therapy

Component therapy is guided by laboratory values, viscoelastic parameters, and clinical bleeding:

• Platelet transfusion: Transfuse for counts below 50,000/mcL with active bleeding or planned procedure. In non-bleeding patients, a threshold of 20,000/mcL is generally used. Platelet consumption in DIC is rapid; repeat counts within hours of transfusion to assess response.
• Fibrinogen replacement: Cryoprecipitate (10 units typical adult dose) or fibrinogen concentrate for fibrinogen below 150 mg/dL. In active DIC with bleeding, target fibrinogen above 200 mg/dL. Fibrinogen is the first factor to reach critically low levels in consumptive coagulopathy and is the single most useful lab value for tracking DIC severity.
• Fresh frozen plasma: For INR greater than 1.5 with active bleeding or planned invasive procedure. Dose 10-15 mL/kg. FFP replaces all coagulation factors but adds volume; in fluid-overloaded patients, consider prothrombin complex concentrate if available.

Viscoelastic-Guided Resuscitation

ROTEM/TEG-guided transfusion algorithms reduce empiric blood product usage and improve outcomes in trauma populations ^[9]. In a pragmatic randomized trial, goal-directed hemostatic resuscitation guided by thromboelastography reduced mortality, achieved more hemostasis, and used less plasma and platelets compared to conventional coagulation assay-guided therapy ^[9]. Extrapolation to burns is reasonable given the overlapping pathophysiology of traumatic and burn-induced coagulopathy, though burn-specific prospective data remain limited. Viscoelastic testing is particularly valuable in burns because conventional coagulation assays (PT, PTT) reflect only the initiation phase of clot formation and miss deficits in clot strength, fibrinolysis, and platelet function that viscoelastic testing captures.

Antithrombin and Recombinant Thrombomodulin

A meta-analysis evaluating antithrombin (AT) and recombinant human thrombomodulin (rhTM) demonstrated that both agents improved DIC resolution rates (AT: OR 5.21; rhTM: OR 1.76) without significantly increasing bleeding, though neither showed a mortality benefit ^[4]. These agents are not standard of care in U.S. burn practice. Consideration of AT or rhTM should prompt hematology consultation.

DIC Monitoring

Serial laboratory monitoring is essential to track DIC trajectory and guide ongoing management:

• Fibrinogen: The most sensitive early marker. Trending fibrinogen every 6-8 hours in active DIC guides replacement therapy and signals improvement or deterioration before other markers change.
• D-dimer: Reflects ongoing fibrinolysis. Extremely elevated values (greater than 10x upper limit of normal) support the diagnosis; trending values track disease activity.
• Platelet count: Serial counts every 6-12 hours. The rate of decline matters more than a single value. A rapidly falling count indicates ongoing consumption and worsening DIC.
• PT/INR: Prolongation reflects factor consumption. Trend alongside fibrinogen to distinguish DIC (fibrinogen falling, PT rising) from dilutional coagulopathy (both improving with resuscitation).

Trending matters more than single values. A fibrinogen of 180 mg/dL that was 250 six hours ago demands different management than a fibrinogen of 180 that was 120 six hours ago.

When to Involve Hematology

Consult hematology for refractory DIC not improving with source control and component therapy, consideration of antithrombin or rhTM, suspected rare coagulation disorders (acquired hemophilia, thrombotic thrombocytopenic purpura), and DIC with concurrent need for therapeutic anticoagulation.

Controversies and Evidence Gaps

No DIC scoring system has been validated specifically for burn populations; existing criteria were developed in sepsis and trauma cohorts. The role of viscoelastic-guided transfusion algorithms in burns is promising but lacks prospective trial data. Whether anticoagulant therapies (AT, rhTM) should be used prophylactically in high-risk burn patients to prevent DIC progression remains undefined. The interaction between massive fluid resuscitation and dilutional coagulopathy versus consumptive DIC is poorly characterized. Optimal timing of surgical excision as a means of reducing DIC risk has not been studied in controlled trials.

References

[1] Skakun PV et al. "Development and Validation of the Clinical Risk Prediction Model for Disseminated Intravascular Coagulation after Severe Burn Injury." Ann Burns Fire Disasters 2025;38(3):222-228. PMID: 41479627 [2] Koami H et al. "Thromboelastometric Analysis of the Correlation Between Burn-Induced Coagulopathy and Severity of Burn Injury." Cureus 2024;16(2):e54489. PMID: 38516476 [3] Umemura Y et al. "Mortality, diagnosis, and etiology of disseminated intravascular coagulation-a systematic review and meta-analysis." J Thromb Haemost 2025;23(8):2663-2679. PMID: 40383152 [4] Li W et al. "Efficacy and safety of antithrombin or recombinant human thrombomodulin in the treatment of disseminated intravascular coagulation: A systematic review and meta-analysis." Thromb Res 2025;249:109302. PMID: 40068332 [5] Wilhelm G et al. "The Crossroads of the Coagulation System and the Immune System: Interactions and Connections." Int J Mol Sci 2023;24(16). PMID: 37628744 [6] Li Q et al. "Establishment and validation of a risk prediction model for disseminated intravascular coagulation patients with electrical burns." Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi 2023;39(8):738-745. PMID: 37805784 [7] Taylor FB Jr et al. "Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation." Thromb Haemost 2001;86(5):1327-1330. PMID: 11816725 [8] Levi M, Ten Cate H. "Disseminated intravascular coagulation." N Engl J Med 1999;341(8):586-592. PMID: 10451465 [9] Gonzalez E et al. "Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays." Ann Surg 2016;263(6):1051-1059. PMID: 26720428